<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37508966</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-3425</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Brain sciences</Title><ISOAbbreviation>Brain Sci</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Survivors Are Still in Need of Neuropsychiatric Support Two Years after Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1034</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/brainsci13071034</ELocationID><Abstract><AbstractText>COVID-19 survivors have been reported to be at risk of long-term neuropsychiatric sequalae; however, prospective evidence in this regard is lacking. We prospectively assessed the occurrence of mental-health-domain-related symptoms over a 24-month period following COVID-19 onset in a cohort of 230 patients. Of them, 36.1% were still presenting with at least one symptom 24 months later. Across the study period, a significant reduction in overall symptoms from the onset was observed (<i>p</i> &lt; 0.001); however, symptom prevalence was unchanged between the 12- and 24-month follow-ups across most symptomatic domains. At the 24-month follow-up, mental-health-domain-related symptoms only were higher than at the onset and were the most frequently reported symptoms. Dyspnea at the onset predicted both symptoms of psychiatric disorders (OR = 3.26, 95% CI = 1.22-8.70, and <i>p</i> = 0.019) and a lack of concentration and focus (OR = 3.17, 95% CI = 1.40-7.16, and <i>p</i> = 0.005) 24 months post-infection, with the number of comorbidities at the onset also predicting the occurrence of a lack of concentration and focus (OR = 1.52, 95% CI = 1.12-2.08, and <i>p</i> = 0.008). The findings of this study may have important public health implications, as they underlie the fact that COVID-19 survivors are still in need of neuropsychiatric support two years after infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colizzi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6139-1920</Identifier><AffiliationInfo><Affiliation>Unit of Psychiatry, Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peghin</LastName><ForeName>Maddalena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4640-679X</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine (DAME), University of Udine, and Friuli Centrale University Health Service (ASUFC), 33100 Udine, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Department of Medicine and Surgery, University of Insubria-ASST-Sette Laghi, 21110 Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Martino</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0445-9578</Identifier><AffiliationInfo><Affiliation>Division of Medical Statistic, Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bontempo</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine (DAME), University of Udine, and Friuli Centrale University Health Service (ASUFC), 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiappinotto</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4829-1831</Identifier><AffiliationInfo><Affiliation>Department of Medicine (DAME), School of Nursing, University of Udine, 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonda</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3818-9676</Identifier><AffiliationInfo><Affiliation>Department of Medicine (DAME), School of Nursing, University of Udine, 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isola</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6391-1720</Identifier><AffiliationInfo><Affiliation>Division of Medical Statistic, Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tascini</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine (DAME), University of Udine, and Friuli Centrale University Health Service (ASUFC), 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balestrieri</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Psychiatry, Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palese</LastName><ForeName>Alvisa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3508-844X</Identifier><AffiliationInfo><Affiliation>Department of Medicine (DAME), School of Nursing, University of Udine, 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20178S4EK9</GrantID><Agency>PRIN</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Sci</MedlineTA><NlmUniqueID>101598646</NlmUniqueID><ISSNLinking>2076-3425</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anxiety</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">insomnia</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword></KeywordList><CoiStatement>M.C. has been a consultant/advisor to GW Pharma Limited, GW Pharma Italy SRL, and F. Hoffmann-La Roche Limited outside of this work. M.P. reports receiving grants and personal fees from Pfizer, MSD, Menarini, and Dia Sorin outside of this work. C.T. has received grants in the last two years from Correvio, Biotest, Biomerieux, Gilead, Angelini, MSD, Pfizer, Thermofisher, Zambon, Shionogi, Avir Pharma, and Hikma outside of this work. All of the other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37508966</ArticleId><ArticleId IdType="pmc">PMC10377179</ArticleId><ArticleId IdType="doi">10.3390/brainsci13071034</ArticleId><ArticleId IdType="pii">brainsci13071034</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prati G., Mancini A.D. The psychological impact of COVID-19 pandemic lockdowns: A review and meta-analysis of longitudinal studies and natural experiments. Psychol. Med. 2021;51:201&#x2013;211. doi: 10.1017/S0033291721000015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291721000015</ArticleId><ArticleId IdType="pmc">PMC7844215</ArticleId><ArticleId IdType="pubmed">33436130</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmann L.M., Adams S., Taylor G. Investigating the prevalence of anxiety and depression during the first COVID-19 lockdown in the United Kingdom: Systematic review and meta-analyses. Br. J. Clin. Psychol. 2022;61:757&#x2013;780. doi: 10.1111/bjc.12360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjc.12360</ArticleId><ArticleId IdType="pmc">PMC9111383</ArticleId><ArticleId IdType="pubmed">35137427</ArticleId></ArticleIdList></Reference><Reference><Citation>Colizzi M., Peghin M., De Martino M., Bontempo G., Gerussi V., Palese A., Isola M., Tascini C., Balestrieri M. Mental health symptoms one year after acute COVID-19 infection: Prevalence and risk factors. Rev. Psiquiatr. Salud Ment. 2023;16:38&#x2013;46. doi: 10.1016/j.rpsm.2022.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpsm.2022.05.008</ArticleId><ArticleId IdType="pmc">PMC9212931</ArticleId><ArticleId IdType="pubmed">35755492</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2021;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Badenoch J.B., Rengasamy E.R., Watson C., Jansen K., Chakraborty S., Sundaram R.D., Hafeez D., Burchill E., Saini A., Thomas L., et al. Persistent neuropsychiatric symptoms after COVID-19: A systematic review and meta-analysis. Brain Commun. 2022;4:fcab297. doi: 10.1093/braincomms/fcab297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab297</ArticleId><ArticleId IdType="pmc">PMC8833580</ArticleId><ArticleId IdType="pubmed">35169700</ArticleId></ArticleIdList></Reference><Reference><Citation>Khademi M., Vaziri-Harami R., Shams J. Prevalence of Mental Health Problems and Its Associated Factors Among Recovered COVID-19 Patients During the Pandemic: A Single-Center Study. Front. Psychiatry. 2021;12:602244. doi: 10.3389/fpsyt.2021.602244.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2021.602244</ArticleId><ArticleId IdType="pmc">PMC8044784</ArticleId><ArticleId IdType="pubmed">33868043</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyraz B., Poyraz C.A., Olgun Y., G&#xfc;rel &#xd6;., Alkan S., &#xd6;zdemir Y.E., Balkan &#x130;., Karaali R. Psychiatric morbidity and protracted symptoms after COVID-19. Psychiatry Res. 2021;295:113604. doi: 10.1016/j.psychres.2020.113604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2020.113604</ArticleId><ArticleId IdType="pmc">PMC7695976</ArticleId><ArticleId IdType="pubmed">33296818</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., Palese A., Venturini M., De Martino M., Gerussi V., Graziano E., Bontempo G., Marrella F., Tommasini A., Fabris M., et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin. Microbiol. Infect. 2021;27:1507&#x2013;1513. doi: 10.1016/j.cmi.2021.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.033</ArticleId><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Steardo L., Zorec R., Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiol. 2020;229:e13473. doi: 10.1111/apha.13473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.13473</ArticleId><ArticleId IdType="pmc">PMC7228251</ArticleId><ArticleId IdType="pubmed">32223077</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M., Canoll P.D., Klein R.S. How COVID-19 Affects the Brain. JAMA Psychiatry. 2021;78:682&#x2013;683. doi: 10.1001/jamapsychiatry.2021.0500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2021.0500</ArticleId><ArticleId IdType="pmc">PMC9894299</ArticleId><ArticleId IdType="pubmed">33769431</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>